Publications by authors named "Changlu Hu"

Claim this Profile
G
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials.
Jian Li, Zhenghang Wang, Jing Huang, Yi Ba, Baoshan Cao, Wenhua Li, Chunmei Bai, Liangjun Zhu, Zhihua Li, Changlu Hu, Chenghui Huang, Huaqiu Shi, Wenhui Pan, Shuang Lu

Lancet Gastroenterol Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.
Xiaojie Bian, Tiejun Yang, Huaqi Yin, Bin Hu, Kai Yao, Shusuan Jiang, Changlu Hu, Yi Zhu, Hai Zhu

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
Changsong Qi, Chang Liu, Zhi Peng, Yanqiao Zhang, Jia Wei, Tianshu Liu, Changlu Hu, Shubin Wang

Lancet· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.
Xiaotian Zhang, Jufeng Wang, Gang Wang, Yanqiao Zhang, Qingxia Fan, Chuangxin Lu, Changlu Hu, Yongqian Shu, Dan Zhu

JAMA· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors.
Mingchuan Zhao, Xichun Hu, Pengpeng Zhuang, Aiping Zeng, Yan Yu, Weihua Yang, Huaqiu Shi, Changlu Hu, Baihui Hu

J Bone Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glecirasib in KRAS-mutated nonsmall-cell lung cancer: a phase 2b trial.
Yuankai Shi, Jian Fang, Ligang Xing, Yu Yao, Jian Zhang, Changlu Hu, Zhihua Liu, Zhihua Li, Wu Zhuang, Yanping Hu, Hui Zhao, Chunmei Bai, Weiguo Hu

Nat Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.
Binghe Xu, Qingyuan Zhang, Yang Luo, Zhongsheng Tong, Tao Sun, Shusen Wang, Xiaohua Zeng, Changlu Hu

Nat Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of suvemcitug, envafolimab, and FOLFIRI in microsatellite-stable or mismatch repair-proficient colorectal cancer: preliminary results of a phase 2 study.
Ying Liu, Jufeng Wang, Yong Fang, Yanhong Deng, Changlu Hu, Shuguang Sun

Int J Colorectal Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma.
Wang Qu, Cheng Fu, Weiqing Han, Hong Luo, Jizhong Quan, Changlu Hu, Hailong Hu

Eur J Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
Yuankai Shi, Jianhua Chen, Runxiang Yang, Hongbo Wu, Zhehai Wang, Weihua Yang, Chunling Liu, Changlu Hu, Ranhua Cao, Hui Li

J Thorac Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Manure replacing synthetic fertilizer improves crop yield sustainability and reduces carbon footprint under winter wheat-summer maize cropping system.
Jincan Niu, Qudsia Saeed, Wenning Wang, Runze Zhang, Lin Liu, Changlu Hu, Hu Xu, Benhua Sun, Shulan Zhang

J Environ Manage· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
Xinan Sheng, Lin Wang, Zhisong He, Yanxia Shi, Hong Luo, Changlu Hu, Guohua Yu, Yi Hu

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Black carbon derived from pyrolysis of maize straw and polystyrene microplastics affects soil biodiversity.
Changlu Hu, Fadan Lei, Xue Zhang, Jiabao Shi, Jing Li, Shuxing Li, Zhuozhi Ouyang

Sci Total Environ· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer.
Huizi Lei, Yun Ling, Pei Yuan, Xieqiao Yan, Lin Wang, Guohua Yu, Changlu Hu, Chuanliang Cui

J Natl Cancer Cent· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Pin Zhang, Qingyuan Zhang, Zhongsheng Tong, Tao Sun, Wei Li, Xichun Hu, Xiaohua Zeng, Changlu Hu, Wenhua Wei, Xiaoyu Zhu

Lancet Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).
Yuankai Shi, Jianhua Chen, Helong Zhang, Zhihong Zhang, Yiping Zhang, Shucai Zhang, Chunling Liu, Changlu Hu, Yanping Hu, Weihua Yang, Huaize Geng, Hui Li

BMC Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study.
Yuankai Shi, Xintian Qin, Xingchen Peng, Aiping Zeng, Jingao Li, Chuanben Chen, Lizhu Lin, Jianli Huang, Hui Wu, Changlu Hu, Zhonghua Yu, Guangyuan Hu, Shanghua Jing, Renhua Guo, Jianhua Shi, Xiuhua Sun

Lancet Reg Health West Pac· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study).
Yuanyuan Zhao, Yunpeng Yang, Fangfang Gao, Changlu Hu, Diansheng Zhong, Jie Zhu, Chunbin Wang, Yan Huang

EClinicalMedicine· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial.
Yayun Cui, Yifu He, Changlu Hu, Congyin Tu, Jin Huang, Xiaofeng Zhu, Chunbao Zang

Front Pharmacol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficient circulating immunoscore predicts prognosis of patients with advanced gastrointestinal cancer.
Yamei Zhao, Yan Tang, Hanlin Qin, Kehai Feng, Changlu Hu

World J Surg Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partial-film mulch returns the same gains in yield and water use efficiency as full-film mulch with reduced cost and lower pollution: a meta-analysis.
Tong Lei, Caixia Luo, Runze Zhang, Changlu Hu, Jiaxing Xu, Shulan Zhang

J Sci Food Agric· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Yuankai Shi, Kaijian Lei, Yuming Jia, Bingqiang Ni, Zhiyong He, Jianhua Shi, Yongqian Shu, Xiaoli Zhu, Shuhua Han, Changlu Hu, Yinghua Ji, Shuyang Zhu, Hua Zhang, Shumin Wang

Cancer Commun (Lond)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High expression of aldolase A is associated with tumor progression and poor prognosis in hepatocellular carcinoma.
Yan Tang, Xuefeng Yang, Kehai Feng, Changlu Hu, Suyi Li

J Gastrointest Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Xinan Sheng, Xieqiao Yan, Lin Wang, Yanxia Shi, Xin Yao, Guohua Yu, Changlu Hu, Chuanliang Cui

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LncRNA MCM3AP-AS1 promotes breast cancer progression via modulating miR-28-5p/CENPF axis.
Qi Chen, Huachao Xu, Jiang Zhu, Kehai Feng, Changlu Hu

Biomed Pharmacother· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis